Evidence map›Paper›PMID 40296901›Full record

ArticleOncology research2025

The synergistic antitumor effect of Karanahan technology and

Vera Ruzanova, Anastasia Proskurina, Genrikh Ritter, Evgeniya Dolgova, Sofya Oshikhmina, Svetlana Kirikovich, Evgeniy Levites, Yaroslav Efremov, Oleg Taranov, Alexandr Ostanin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vera RuzanovaLaboratory of Induced Cellular Processes, Institute of Cytology and Genetics SB RAS, Novosibirsk, 630090, Russia.
Anastasia ProskurinaLaboratory of Induced Cellular Processes, Institute of Cytology and Genetics SB RAS, Novosibirsk, 630090, Russia.
Genrikh RitterLaboratory of Induced Cellular Processes, Institute of Cytology and Genetics SB RAS, Novosibirsk, 630090, Russia.
Evgeniya DolgovaLaboratory of Induced Cellular Processes, Institute of Cytology and Genetics SB RAS, Novosibirsk, 630090, Russia.
Sofya OshikhminaLaboratory of Induced Cellular Processes, Institute of Cytology and Genetics SB RAS, Novosibirsk, 630090, Russia.
Svetlana KirikovichLaboratory of Induced Cellular Processes, Institute of Cytology and Genetics SB RAS, Novosibirsk, 630090, Russia.
Evgeniy LevitesLaboratory of Induced Cellular Processes, Institute of Cytology and Genetics SB RAS, Novosibirsk, 630090, Russia.
Yaroslav EfremovNovosibirsk National Research State University, Novosibirsk, 630090, Russia.
Oleg TaranovDepartment of Microscopic Research, State Research Center of Virology and Biotechnology "Vector", Koltsovo, 630559, Russia.
Alexandr OstaninLaboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, 630099, Russia.
Elena ChernykhLaboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, 630099, Russia.
Nikolay KolchanovDepartment of Systems Biology, Institute of Cytology and Genetics SB RAS, Novosibirsk, 630090, Russia.
Sergey BogachevLaboratory of Induced Cellular Processes, Institute of Cytology and Genetics SB RAS, Novosibirsk, 630090, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Currently, there exist two approaches to the treatment of malignant neoplasms: the Karanahan technology and Methods: BALB/c mice grafted with B-cellular lymphoma A20 were treated using the Karanahan technology consisting of intraperitoneal cyclophosphamide administrations and intratumoral DNA injections according to an individually determined therapeutic regimen, together with Results: When αOX40 was administered 5 h after each treatment using the Karanahan technology, mass death of mice caused by systemic inflammation and multiple organ failure was observed. The state of blood cells after the treatment using the Karanahan technology at the time points corresponding to antibody injections was analyzed to elucidate the reasons for this effect. It was found that at some time points, there occurs activation of the immune system and a powerful release (up to 16%) of monocytes and granulocytes carrying Fc receptor and OX40 on their surface into blood; when interacting with αOX40, they can activate the lytic potential of these cells. Activation of neutrophils to NETosis was also observed. Based on these findings, a study was carried out in different time regimes to combine the Karanahan technology and αOX40 injections. When αOX40 was injected into the points of minimal release of myeloid cells into the blood, increased survival rate and the greatest antitumor efficacy were observed: 37% of animals survived without relapses on day 100 after experiment initiation.

Indexed as

Antibodies, MonoclonalCancer VaccinesLymphoma, B-CellReceptors, OX40AnimalsCell Line, TumorCombined Modality TherapyCyclophosphamideFemaleHumansMiceMice, Inbred BALB CVaccinationXenograft Model Antitumor AssaysAntibodies, MonoclonalCancer VaccinesCyclophosphamideReceptors, OX40Antitumor immunityKaranahan technologyOX40Systemic inflammatory reactionTumor-initiating stem cells

Identifiers

PMID40296901
PMCPMC12034020

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.